Jazz Pharmaceuticals plc

NasdaqGS:JAZZ 주식 보고서

시가총액: US$6.4b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Jazz Pharmaceuticals 관리

관리 기준 확인 3/4

Jazz Pharmaceuticals' CEO는 Bruce Cozadd, Jan2003 에 임명되었습니다 의 임기는 21.42 년입니다. 총 연간 보상은 $ 15.34M, 7.8% 로 구성됩니다. 7.8% 급여 및 92.2% 보너스(회사 주식 및 옵션 포함). 는 $ 35.61M 가치에 해당하는 회사 주식의 0.5% 직접 소유합니다. 35.61M. 경영진과 이사회의 평균 재임 기간은 각각 4.8 년과 11.5 년입니다.

주요 정보

Bruce Cozadd

최고 경영자

US$15.3m

총 보상

CEO 급여 비율7.8%
CEO 임기21.5yrs
CEO 소유권0.5%
경영진 평균 재임 기간4.9yrs
이사회 평균 재임 기간11.6yrs

최근 관리 업데이트

Recent updates

Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Has A Meaningful Debt Burden

Jun 23
Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Has A Meaningful Debt Burden

Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues

Jun 21

Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off

Apr 15

Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price

Apr 02
Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price

Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?

Feb 18
Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?

Updated View On Jazz Pharmaceuticals' 2025 Goals

Jan 29

Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking

Dec 26
Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking

Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly

Oct 31
Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly

Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

Jul 12
Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt

Apr 12
We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt

Jazz Pharmaceuticals: Monopoly In The Narcolepsy Drug Market

Aug 24

Jazz begins phase 3 trial of cannabis drug Epidiolex for rare epilepsy

Aug 18

Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly

Aug 10
Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly

Jazz Pharmaceuticals: Strong Launch Of Xywav In Idiopathic Hypersomnia

Jun 08

Jazz Pharmaceuticals (NASDAQ:JAZZ) Takes On Some Risk With Its Use Of Debt

May 12
Jazz Pharmaceuticals (NASDAQ:JAZZ) Takes On Some Risk With Its Use Of Debt

CEO 보상 분석

Bruce Cozadd 의 보수는 Jazz Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

US$331m

Dec 31 2023US$15mUS$1m

US$415m

Sep 30 2023n/an/a

US$80m

Jun 30 2023n/an/a

-US$87m

Mar 31 2023n/an/a

-US$156m

Dec 31 2022US$17mUS$1m

-US$224m

Sep 30 2022n/an/a

-US$19m

Jun 30 2022n/an/a

-US$52m

Mar 31 2022n/an/a

-US$450m

Dec 31 2021US$16mUS$1m

-US$330m

Sep 30 2021n/an/a

-US$161m

Jun 30 2021n/an/a

US$40m

Mar 31 2021n/an/a

US$518m

Dec 31 2020US$13mUS$1m

US$239m

Sep 30 2020n/an/a

US$179m

Jun 30 2020n/an/a

US$133m

Mar 31 2020n/an/a

US$280m

Dec 31 2019US$15mUS$1m

US$523m

Sep 30 2019n/an/a

US$609m

Jun 30 2019n/an/a

US$656m

Mar 31 2019n/an/a

US$486m

Dec 31 2018US$11mUS$979k

US$447m

Sep 30 2018n/an/a

US$520m

Jun 30 2018n/an/a

US$434m

Mar 31 2018n/an/a

US$447m

Dec 31 2017US$10mUS$950k

US$488m

보상 대 시장: Bruce 의 총 보상 ($USD 15.34M )은 US 시장( $USD 8.45M ).

보상과 수익: Bruce 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.


CEO

Bruce Cozadd (60 yo)

21.5yrs

테뉴어

US$15,341,235

보상

Mr. Bruce C. Cozadd serves as an Independent Director of Acelyrin, Inc. since March 7, 2022 and also serves as its Chairman of Board since January 2023. He served as Member of Board of Advisors at Cellares...


리더십 팀

이름위치테뉴어보상소유권
Bruce Cozadd
Co-Founder21.5yrsUS$15.34m0.50%
$ 32.0m
Renee Gala
President & COOless than a yearUS$5.43m0.026%
$ 1.7m
Patricia Carr
Senior VP & Chief Accounting Officer4.9yrsUS$1.40m데이터 없음
Neena Patil
Executive VP & Chief Legal Officer5yrsUS$3.88m0.017%
$ 1.1m
Robert Iannone
Executive VP and Global Head of Research & Development5.2yrsUS$4.98m0.045%
$ 2.9m
Philip Johnson
Executive VP & CFOless than a year데이터 없음0.019%
$ 1.2m
Andrea Flynn
VP & Head of Investor Relationsno data데이터 없음데이터 없음
Heidi Manna
Executive VP & Chief People Officer5.7yrs데이터 없음데이터 없음
Jed Black
Senior Vice President of Sleep & CNS Medicineno data데이터 없음데이터 없음
Samantha Pearce
Senior Vice President of Europe & International4.3yrs데이터 없음0.023%
$ 1.4m
John Miller
Senior Vice President of Corporate Strategy4.8yrs데이터 없음데이터 없음
Mary Henderson
Senior Vice President of Technical Operationsless than a year데이터 없음데이터 없음

4.9yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 관리: JAZZ 의 관리팀은 경험 ( 4.8 년 평균 재직 기간)으로 간주됩니다.


이사회 구성원

이름위치테뉴어보상소유권
Bruce Cozadd
Co-Founder21.5yrsUS$15.34m0.50%
$ 32.0m
Kenneth O'Keefe
Independent Director20.5yrsUS$513.77k0.041%
$ 2.6m
Seamus Mulligan
Independent Director12.5yrsUS$531.27k1.85%
$ 118.4m
Peter Gray
Independent Director11.2yrsUS$533.77k0.021%
$ 1.3m
Norbert Riedel
Independent Director11.2yrsUS$533.77k0.017%
$ 1.1m
Patrick Gerald Enright
Independent Director15yrsUS$526.27k0.028%
$ 1.8m
Rick Winningham
Lead Independent Director14.2yrsUS$571.27k0.012%
$ 746.6k
Jennifer Cook
Independent Non-Executive Director3.6yrsUS$533.77k0.0060%
$ 386.4k
Catherine Sohn
Independent Director12yrsUS$523.77k0.019%
$ 1.2m
Heather McSharry
Independent Director11.2yrsUS$543.77k0.022%
$ 1.4m
Mark Smith
Independent Non-Executive Director3.6yrsUS$521.27k0.0060%
$ 386.4k
Anne O'Riordan
Independent Director5.4yrsUS$523.77k0.015%
$ 959.9k

11.6yrs

평균 재임 기간

63.5yo

평균 연령

경험이 풍부한 이사회: JAZZ 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 11.5 년).